Cargando…

MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review

MircoRNA (miRNA) are a group of small, non–coding, regulatory RNA with an average length of approximately 22 nucleotides, which mostly modulate gene expression post–transcriptionally through complementary binding to the 3ʹ‐untranslated region (3ʹ‐UTR) of multiple target genes. Emerging evidence has...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Wenxiu, Hua, Yuting, Deng, Fei, Wang, Dandan, Wu, Yang, Zhang, Wei, Tang, Jinhai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469794/
https://www.ncbi.nlm.nih.gov/pubmed/32506767
http://dx.doi.org/10.1111/cas.14517
_version_ 1783578466892906496
author Xu, Wenxiu
Hua, Yuting
Deng, Fei
Wang, Dandan
Wu, Yang
Zhang, Wei
Tang, Jinhai
author_facet Xu, Wenxiu
Hua, Yuting
Deng, Fei
Wang, Dandan
Wu, Yang
Zhang, Wei
Tang, Jinhai
author_sort Xu, Wenxiu
collection PubMed
description MircoRNA (miRNA) are a group of small, non–coding, regulatory RNA with an average length of approximately 22 nucleotides, which mostly modulate gene expression post–transcriptionally through complementary binding to the 3ʹ‐untranslated region (3ʹ‐UTR) of multiple target genes. Emerging evidence has shown that miRNA are frequently dysregulated in a variety of human malignancies. Among them, microRNA‐145 (miR‐145) has been increasingly identified as a critical suppressor of carcinogenesis and therapeutic resistance. Resistance to tumor therapy is a challenge in cancer treatment due to the daunting range of resistance mechanisms. We reviewed the status quo of recent advancements in the knowledge of the functional role of miR‐145 in therapeutic resistance and the tumor microenvironment. It may serve as an innovative biomarker for therapeutic response and cancer prognosis.
format Online
Article
Text
id pubmed-7469794
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74697942020-09-09 MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review Xu, Wenxiu Hua, Yuting Deng, Fei Wang, Dandan Wu, Yang Zhang, Wei Tang, Jinhai Cancer Sci Review Articles MircoRNA (miRNA) are a group of small, non–coding, regulatory RNA with an average length of approximately 22 nucleotides, which mostly modulate gene expression post–transcriptionally through complementary binding to the 3ʹ‐untranslated region (3ʹ‐UTR) of multiple target genes. Emerging evidence has shown that miRNA are frequently dysregulated in a variety of human malignancies. Among them, microRNA‐145 (miR‐145) has been increasingly identified as a critical suppressor of carcinogenesis and therapeutic resistance. Resistance to tumor therapy is a challenge in cancer treatment due to the daunting range of resistance mechanisms. We reviewed the status quo of recent advancements in the knowledge of the functional role of miR‐145 in therapeutic resistance and the tumor microenvironment. It may serve as an innovative biomarker for therapeutic response and cancer prognosis. John Wiley and Sons Inc. 2020-07-08 2020-09 /pmc/articles/PMC7469794/ /pubmed/32506767 http://dx.doi.org/10.1111/cas.14517 Text en © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Review Articles
Xu, Wenxiu
Hua, Yuting
Deng, Fei
Wang, Dandan
Wu, Yang
Zhang, Wei
Tang, Jinhai
MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review
title MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review
title_full MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review
title_fullStr MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review
title_full_unstemmed MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review
title_short MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review
title_sort mir‐145 in cancer therapy resistance and sensitivity: a comprehensive review
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469794/
https://www.ncbi.nlm.nih.gov/pubmed/32506767
http://dx.doi.org/10.1111/cas.14517
work_keys_str_mv AT xuwenxiu mir145incancertherapyresistanceandsensitivityacomprehensivereview
AT huayuting mir145incancertherapyresistanceandsensitivityacomprehensivereview
AT dengfei mir145incancertherapyresistanceandsensitivityacomprehensivereview
AT wangdandan mir145incancertherapyresistanceandsensitivityacomprehensivereview
AT wuyang mir145incancertherapyresistanceandsensitivityacomprehensivereview
AT zhangwei mir145incancertherapyresistanceandsensitivityacomprehensivereview
AT tangjinhai mir145incancertherapyresistanceandsensitivityacomprehensivereview